HEDoctoral network2026–2029

HER-CARE · Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management

Horizon Europe — Marie Skłodowska-Curie Actions

Duration: 2026-01-01 → 2029-12-31
EU contribution: €4,697,517
Participants: 33
Scheme: HORIZON-TMA-MSCA-DN

Lines connect the coordinator with its partners.

Project objective

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes. HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling. These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment.HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.

Original text from CORDIS.

Participants

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS · AmsterdamCoordinatorNetherlands
ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
ASTRAZENECA UK LIMITED · CAMBRIDGEUnited Kingdom
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO · BarcelonaSpain
EVIDENCIO BV · HaaksbergenNetherlands
FOUNDATION FOR GENOMICS & POPULATION HEALTH · CambridgeUnited Kingdom
INSTITUT GUSTAVE ROUSSY · VillejuifFrance
INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG · LondonUnited Kingdom
JOHNS HOPKINS UNIVERSITY · BaltimoreUnited States
KAROLINSKA INSTITUTET · STOCKHOLMSweden
KLINIKUM DER UNIVERSITAET ZU KOELN · KoelnGermany
KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIA · AGIOS DOMETIOSCyprus
MEDIZINISCHE UNIVERSITAET WIEN · WienAustria
Masarykova univerzita · BrnoCzechia
Methylomics B.V. · NootdorpNetherlands
OXFORD NANOPORE TECHNOLOGIES LTD · OxfordUnited Kingdom
PROTEOTYPE DIAGNOSTICS LTD · CambridgeUnited Kingdom
QIMR Berghofer Medical Research Institute · HerstonAustralia
REGION SYDDANMARK · VejleDenmark
SIEMENS HEALTHINEERS AG · FORCHHEIMGermany
STICHTING KONINGIN WILHELMINA FONDS VOOR DE NEDERLANDSE KANKERBESTRIJDING · AMSTERDAMNetherlands
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM · NijmegenNetherlands
STREMBLE VENTURES LTD · LIMASSOLCyprus
SYDDANSK UNIVERSITET · Odense MDenmark
Sophia Genetics SA · Saint-SulpiceSwitzerland
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGEUnited Kingdom
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordUnited Kingdom
UNIVERSITAT DE BARCELONA · BarcelonaSpain
UNIVERSITE PARIS-SACLAY · Gif-Sur-YvetteFrance
UNIVERSITEIT TWENTE · EnschedeNetherlands
UNIVERSITEIT UTRECHT · UtrechtNetherlands
Veracyte, Inc. · South San FranciscoUnited States
iCAD, Inc · NashuaUnited States

HER-CARE · Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management

Project objective

Participants

Links